Risedronic acid

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 578041

CAS#: 105462-24-6

Description: Risedronic acid is a bisphosphonate used to strengthen bone, treat or prevent osteoporosis, and treat Paget's disease of bone.

Chemical Structure

img
Risedronic acid
CAS# 105462-24-6
Instruction

Theoretical Analysis

MedKoo Cat#: 578041
Name: Risedronic acid
CAS#: 105462-24-6
Chemical Formula: C7H11NO7P2
Exact Mass: 283.00
Molecular Weight: 283.110
Elemental Analysis: C, 29.70; H, 3.92; N, 4.95; O, 39.56; P, 21.88

Price and Availability

This product is not in stock, which may be available by custom synthesis. For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge). Quote less than 1g will not be provided. To request quote, please email to sales @medkoo.com or click below button.
Note: Price will be listed if it is available in the future.

Request quote for custom synthesis

Synonym: Risedronic acid; Risedronate; NE 58019; NE58019; NE-58019

IUPAC/Chemical Name: (1-Hydroxy-2-(3-pyridyl)ethylidene)diphosphonic acid

InChi Key: IIDJRNMFWXDHID-UHFFFAOYSA-N

InChi Code: InChI=1S/C7H11NO7P2/c9-7(16(10,11)12,17(13,14)15)4-6-2-1-3-8-5-6/h1-3,5,9H,4H2,(H2,10,11,12)(H2,13,14,15)

SMILES Code: OC(Cc1cccnc1)(P(=O)(O)O)P(=O)(O)O

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: To be determined

Shelf Life: >2 years if stored properly

Drug Formulation: To be determined

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

More Info:

Biological target:
In vitro activity:
In vivo activity:

Preparing Stock Solutions

The following data is based on the product molecular weight 283.11 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
In vitro protocol:
In vivo protocol:

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

1: Quesada-Gómez JM, Santiago-Mora R, Navarro-Valverde C, Dorado G, Casado-Díaz A. Stimulation of in-vitro angiogenesis by low concentrations of risedronate is mitigated by 1,25-dihydroxyvitamin D3 or 24,25-dihydroxyvitamin D3. J Steroid Biochem Mol Biol. 2015 Apr;148:214-8. doi: 10.1016/j.jsbmb.2014.10.018. Epub 2014 Nov 1. Review. PubMed PMID: 25445918.

2: Nuti R. Updates on mechanism of action and clinical efficacy of risedronate in osteoporosis. Clin Cases Miner Bone Metab. 2014 Sep;11(3):208-14. Review. PubMed PMID: 25568655; PubMed Central PMCID: PMC4269145.

3: Hemmati I, Wade J, Kelsall J. Risedronate-associated scleritis: a case report and review of the literature. Clin Rheumatol. 2012 Sep;31(9):1403-5. doi: 10.1007/s10067-012-2035-z. Epub 2012 Aug 5. Review. PubMed PMID: 22864810.

4: In brief: delayed-release risedronate (Atelvia). Med Lett Drugs Ther. 2011 Mar 21;53(1360):24. Review. Erratum in: Med Lett Drugs Ther. 2011 Jun 27;53(1367):52. PubMed PMID: 21412209.

5: Iwamoto J, Takeda T, Sato Y, Matsumoto H. Effects of risedronate on osteoarthritis of the knee. Yonsei Med J. 2010 Mar;51(2):164-70. doi: 10.3349/ymj.2010.51.2.164. Epub 2010 Feb 12. Review. PubMed PMID: 20191005; PubMed Central PMCID: PMC2824859.

6: Epstein S, Jeglitsch M, McCloskey E. Update on monthly oral bisphosphonate therapy for the treatment of osteoporosis: focus on ibandronate 150 mg and risedronate 150 mg. Curr Med Res Opin. 2009 Dec;25(12):2951-60. doi: 10.1185/03007990903361307. Review. PubMed PMID: 19835464.

7: Hagino H. [Risedronate for treatment of osteoporosis]. Nihon Rinsho. 2009 May;67(5):948-53. Review. Japanese. PubMed PMID: 19432115.

8: Kishimoto H. [Efficacy and tolerability of risedronate for the treatment of osteoporosis]. Clin Calcium. 2008 Oct;18(10):1417-26. doi: CliCa081014171426. Review. Japanese. PubMed PMID: 18830038.

9: Wells G, Cranney A, Peterson J, Boucher M, Shea B, Robinson V, Coyle D, Tugwell P. Risedronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women. Cochrane Database Syst Rev. 2008 Jan 23;(1):CD004523. doi: 10.1002/14651858.CD004523.pub3. Review. PubMed PMID: 18254053.

10: Soen S. [Evidence of risedronate for treatment of osteoporosis]. Nihon Rinsho. 2007 Nov 28;65 Suppl 9:344-7. Review. Japanese. PubMed PMID: 18161128.

11: Bobba R, Adachi JD. Review of the safety and efficacy of risedronate for the treatment of male osteoporosis. Clin Interv Aging. 2007;2(3):275-82. Review. PubMed PMID: 18044178; PubMed Central PMCID: PMC2685258.

12: Takata S. [Therapeutic effects of risedronate on Paget's disease of bone]. Clin Calcium. 2006 Sep;16(9):1508-12. Review. Japanese. PubMed PMID: 16951476.

13: Recker RR, Barger-Lux J. Risedronate for prevention and treatment of osteoporosis in postmenopausal women. Expert Opin Pharmacother. 2005 Mar;6(3):465-77. Review. PubMed PMID: 15794737.

14: Fukunaga M. [VERT(Vertebral Efficacy with Risedronate Therapy)-MN(Multinational) Study and VERT-NA(North America) Study]. Nihon Rinsho. 2004 Feb;62 Suppl 2:433-6. Review. Japanese. PubMed PMID: 15035166.

15: Fukunaga M. [Risedronate]. Nihon Rinsho. 2003 Feb;61(2):235-9. Review. Japanese. PubMed PMID: 12638214.

16: Deal CL. Risedronate prevents hip fractures, but who should get therapy? Cleve Clin J Med. 2002 Dec;69(12):964, 968-70, 973-6. Review. PubMed PMID: 12546269.

17: Baker DE. Alendronate and risedronate: what you need to know about their upper gastrointestinal tract toxicity. Rev Gastroenterol Disord. 2002;2(1):20-33. Review. PubMed PMID: 12122976.

18: Viñas G, Olivé A, Holgado S, Costa J. [Episcleritis secondary to risedronate]. Med Clin (Barc). 2002 Apr 27;118(15):598-9. Review. Spanish. PubMed PMID: 12015954.

19: Sickels JM, Nip CS. Risedronate for the prevention of fractures in postmenopausal osteoporosis. Ann Pharmacother. 2002 Apr;36(4):664-70. Review. PubMed PMID: 11918518.

20: Dougherty JA. Risedronate for the prevention and treatment of corticosteroid-induced osteoporosis. Ann Pharmacother. 2002 Mar;36(3):512-6. Review. PubMed PMID: 11895066.